KIDNEY TRANSPLANT REJECTION

This study tests two drugs, carfilzomib and belatacept, along with standard steroids and immune-suppressing medicines, in 25 kidney transplant recipients who have signs of rejection. The goal is to see if this combination is safe and can reduce harmful antibodies that attack the …

This study tests whether injecting special stem cells (from donated fat tissue) directly into the kidney's main artery is safe for people whose transplanted kidney is being rejected. The treatment aims to reduce inflammation and control rejection. Only 12 adult kidney transplant …

This study tests whether adding a drug called tocilizumab to the usual treatment (IVIG, plasmapheresis, and rituximab) can better control chronic active antibody-mediated rejection (CAMR) in kidney transplant recipients. CAMR is a serious condition that often leads to kidney loss…

This study compares a new drug, frexalimab, to the standard drug tacrolimus in adults receiving their first kidney transplant. The goal is to see if frexalimab is better at preventing organ rejection and improving kidney function over 5 years. Participants must have low-to-modera…

This study is testing a new blood test called GraftAssureDx to see if it can detect kidney transplant rejection without needing a biopsy. About 125 kidney transplant recipients will provide blood and urine samples, and the test results will be compared to standard biopsy findings…

This study is testing whether a blood test (called DD-cfDNA) can accurately detect kidney transplant rejection, potentially replacing the need for invasive kidney biopsies. Researchers will compare the blood test results with standard biopsy analysis in 300 kidney transplant reci…

This study looks at whether changes in platelet function can signal kidney transplant rejection without needing a biopsy. Researchers will measure platelet activity in 60 adult kidney transplant patients before and after surgery, and compare results with standard biopsy findings.…

This study looks at whether a urine test for a protein called CXCL10 can spot kidney transplant rejection more accurately than current blood tests, especially when the blood test says everything is fine. Researchers will collect urine samples from 50 kidney transplant patients wh…

This study tests whether a blood test that measures donor DNA can help doctors decide when a kidney biopsy is truly needed after a transplant. About 500 kidney transplant recipients will be randomly assigned to standard care or to have their doctors receive this blood test result…